Fukumoto Shinya, Hanazono Kiwamu, Miyasho Taku, Endo Yoshifumi, Kadosawa Tsuyoshi, Iwano Hidetomo, Uchide Tsuyoshi
Veterinary Internal Medicine, Department of Small Animal Clinical Sciences, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido 069-8501,Japan.
Companion Animal Nutrition, Department of Veterinary Sciences, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido 069-8501, Japan.
Life Sci. 2014 Nov 24;118(2):329-32. doi: 10.1016/j.lfs.2014.01.002. Epub 2014 Jan 19.
Many studies of human subjects have demonstrated the utility of assessing serum levels of endothelin-1 (ET-1) and big ET-1 as clinical biomarkers in cardiopulmonary and neoplastic diseases. In this study we explored the feasibility of using serum big ET-1 as a reliable veterinary marker in dogs with various cardiopulmonary and neoplastic diseases.
Serum big ET-1 levels were measured by ELISA in dogs with cardiopulmonary (n=21) and neoplastic diseases (n=57). Dogs exhibiting cardiopulmonary disease were divided into two groups based on the velocity of tricuspid valve regurgitation (3.0>m/s) measured by ultrasound: without and with pulmonary hypertension. Big ET-1 levels for the dogs with the diseases were compared with levels in normal healthy dogs (n=17).
Dogs with cardiopulmonary disease (4.6±4.6 pmol/l) showed a significantly (P<0.01) higher level of big ET-1 than healthy control dogs (1.1±0.53 pmol/l). Serum levels in the dogs with pulmonary hypertension (6.2±5.3 pmol/l) were significantly (P<0.01) higher than those without pulmonary hypertension (2.0±0.6 pmol/l). Dogs with hemangiosarcoma (5.6±2.2 pmol/l), adenocarcinoma (2.0±1.8 pmol/l), histiocytic sarcoma (3.3±1.9 pmol/l), chondrosarcoma or osteosarcoma (3.0±1.6 pmol/l) and hepatocellular carcinoma (2.7±1.8 pmol/l) showed significantly (P<0.05) higher levels than healthy control dogs.
These findings point to the potential of serum big ET-1 as a clinical marker for cardiopulmonary and neoplastic diseases in dogs.
许多针对人类受试者的研究已证明，评估血清内皮素 - 1（ET - 1）和大内皮素 - 1水平作为心肺疾病和肿瘤疾病的临床生物标志物具有实用性。在本研究中，我们探讨了将血清大内皮素 - 1用作患有各种心肺疾病和肿瘤疾病犬类的可靠兽医标志物的可行性。
通过酶联免疫吸附测定法（ELISA）测量患有心肺疾病（n = 21）和肿瘤疾病（n = 57）犬类的血清大内皮素 - 1水平。根据超声测量的三尖瓣反流速度（> 3.0 m/s），将患有心肺疾病的犬分为两组：无肺动脉高压组和有肺动脉高压组。将患病犬的大内皮素 - 1水平与正常健康犬（n = 17）的水平进行比较。
患有心肺疾病的犬（4.6±4.6 pmol/l）的大内皮素 - 1水平显著高于健康对照犬（1.1±0.53 pmol/l）（P < 0.01）。患有肺动脉高压的犬（6.2±5.3 pmol/l）的血清水平显著高于无肺动脉高压的犬（2.0±0.6 pmol/l）（P < 0.01）。患有血管肉瘤（5.6±2.2 pmol/l）、腺癌（2.0±1.8 pmol/l）、组织细胞肉瘤（3.3±1.9 pmol/l）、软骨肉瘤或骨肉瘤（3.0±1.6 pmol/l）以及肝细胞癌（2.7±1.8 pmol/l）的犬的血清水平显著高于健康对照犬（P < 0.05）。
这些发现表明血清大内皮素 - 1作为犬类心肺疾病和肿瘤疾病临床标志物的潜力。
